Novo Nordisk sales in diabetes subsegments 2020

Danish drug manufacturer Novo Nordisk’s diabetes subsegment of glucagon-like peptide 1 (GLP-1) products generated nearly 42 billion kroner in 2020. The company’s total insulin-related sales stood at some 56.5 billion kroner, of which long-acting insulins made up the largest share.

…. more: Statista.com (Quelle/Source)